Guardant Health Inc (NASDAQ:GH) Director Ian T. Clark sold 81,772 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $73.90, for a total transaction of $6,042,950.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
GH stock opened at $64.07 on Friday. The company has a market cap of $5.63 billion and a price-to-earnings ratio of -22.88. Guardant Health Inc has a one year low of $27.04 and a one year high of $106.58.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. As a group, sell-side analysts predict that Guardant Health Inc will post -1.5 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Guardant Health in the fourth quarter worth about $26,000. Mascoma Wealth Management LLC purchased a new position in shares of Guardant Health in the first quarter worth about $54,000. SG Americas Securities LLC purchased a new position in shares of Guardant Health in the first quarter worth about $108,000. Financial Advocates Investment Management purchased a new position in shares of Guardant Health in the fourth quarter worth about $220,000. Finally, Legal & General Group Plc purchased a new position in shares of Guardant Health in the fourth quarter worth about $85,000. Institutional investors and hedge funds own 68.60% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Recommended Story: Growth and Income Funds
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.